Remove tag research-sites
article thumbnail

September 30, 2022: CTTI’s Digital Health Trials Hub Recommendations and Resources to Run Your Digital Health Trial (Marianne Chase, MGH, CTTI Team Lead, Jörg Goldhahn, ETH Zurich, CTTI Team Lead)

Rethinking Clinical Trials

Neurological Clinical Research Institute. Digital Health Trials can help research obtain better and more reliable information, conduct more patient-centric research, and move at higher speed and efficiency. Tech support at the site level is important to addressing problems in a study. Marianne Chase. Jörg Goldhahn, MD.

Trials 130
article thumbnail

Grand Rounds June 2, 2023: PROACT Xa and The Wizard of Oz: Behind the Curtain of a Pragmatic Decentralized Clinical Trial (John Alexander, MD, MHS)

Rethinking Clinical Trials

The trial took place at 64 sites, and randomized 863 patients. Sites were selected based on their On-X AVR volume, and the study leveraged the surgeon/patient relationship for recruitment. Several sites could enroll patients from outside of their system, based on regional or state requirements from local IRBs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. McCreary, PharmD, BCIDP)

Rethinking Clinical Trials

UPMC did not allow patients to receive experimental COVID-19 therapies outside of the context of a clinical trial and used the REMAP-CAP platform, a global pragmatic adaptive trial platform, in all clinic sites. Patients were screened by local teams at each site.          Speaker Erin K. Many patients did not answer the phone.

article thumbnail

Johnson & Johnson to Participate in Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

The Pharma Data

Mathai Mammen, Global Head, Research & Development Janssen Research Development will represent the Company in a session scheduled at 9:40 a.m. This site uses cookies as described in our Cookie Policy. Please click the “Accept” button or continue to use our site if you agree to our use of cookies.

article thumbnail

Grand Rounds July 22, 2022: ACTIV-6: 1-Year Later and Trial Results for Ivermectin-400 and Inhaled Fluticasone (Susanna Naggie, MD, MHS)

Rethinking Clinical Trials

Vice Dean for Clinical Research. ACTIV-6 is actively recruiting across 93 sites with 5,034 randomized. The sites had a very clear role, and the training was really important. There was a lot of outreach to sites and they embraced the remote trial. Were there concerns about having patients not associated with a site?

Trials 173
article thumbnail

Grand Rounds May 19, 2023: Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis After a Fracture (Robert O’Toole, MD)

Rethinking Clinical Trials

Researchers aimed to test the safety and effectiveness of Aspirin use as prophylaxis in orthopedic trauma cases. Through the Patient-Centered Outcomes Research Institute (PCORI), the team conducted a Discrete Choice Experiment (DCE), which highlighted patient concern for risk of death compared to risk of complication.

Trials 130
article thumbnail

Grand Rounds July 8, 2022: Results From the COVID-OUT Trial, A Phase-3 Trial of Outpatient Treatment for Covid-19 Using Metformin, Ivermectin, and Fluvoxamine (Carolyn Bramante, MD, MPH; Thomas Murray, PhD; Jared Huling, PhD)

Rethinking Clinical Trials

Core Faculty, Program for Health Disparities Research. We started only looking within the participating health system and sites. We worked together between the sites when there were issues with bandwidth at one of the sites, the main site would call those participants. Carolyn Bramante, MD, MPH. Thomas Murray, PhD.

Trials 130